Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial.

Journal article

The association between virologic response and human immunodeficiency virus type 1 (HIV-1) subtype was investigated in 113 HIV-1-infected children randomly assigned to receive zidovudine plus lamivudine, zidovudine plus abacavir, or lamivudine plus abacavir in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. Symptomatic children (n=68) also received nelfinavir; asymptomatic children (n=45) were randomly assigned to receive nelfinavir or placebo. HIV-1 subtypes A, B, C, D, F, G, H, A/E, and A/G were found in 15%, 41%, 16%, 9%, 5%, 2%, 1%, 5%, and 7% of the children, respectively. Resistance assay failure rates were higher for non-B subtypes than for B subtypes (genotype, P=.01; phenotype, P=.02). HIV-1 subtype was not associated with virologic response at 24 and 48 weeks after initiation of treatment. No differences were observed in the frequency of development of resistance mutations L90M (P=1.00) and D30N (P=.61) in B and non-B viruses. In conclusion, no evidence that subtype determined virologic response to therapy was found.

Authors: Pillay, D; Walker, A; Gibb, D; de Rossi, A; Kaye, S

• Publication status: Published
• Journal: Journal of infectious diseases
• Volume: 186
• Issue: 5
• Pages: 617-625
• Publication date: 2002-09-01
• DOI: 10.1086/342680
• EISSN: 1537-6613
• ISSN: 0022-1899
• Language: English
• Keywords: HIV-1; Child, Preschool; Drug Therapy, Combination; RNA, Viral; HIV Infections; Humans; Antiviral Agents; Reverse Transcriptase Inhibitors; Child; HIV Protease Inhibitors; Drug Resistance; Nelfinavir